ONC
The table below shows BeOne Medicines AG's income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Revenue | $1.51B | $1.41B | $1.32B | $1.12B | $1.00B | $929.17M |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | $1.35B | $1.22B | $1.15B | $952.28M | $831.14M | $791.03M |
| R&D | $541.22M | $523.66M | $524.90M | $481.89M | $496.18M | $454.47M |
BeOne Medicines AG reported annual revenue of $5.34B for fiscal year 2025. That is up 40.2% from $3.81B in fiscal 2024. Over the 10 fiscal years shown, annual revenue grew from $1.07M (FY 2016) to $5.34B. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| SG&A |
| $555.10M |
| $529.00M |
| $537.91M |
| $459.29M |
| $455.22M |
| $443.73M |
| Operating income | $249.90M | $163.11M | $87.89M | $11.10M | -$120.27M | -$107.16M |
| Income tax | $31.86M | $22.32M | $5.23M | $19.63M | $23.05M | $14.48M |
| Net income | $227.36M | $124.84M | $94.32M | $1.27M | -$121.35M | -$120.41M |
| EPS (diluted) | $0.15 | $0.08 | $0.06 | $0.00 | -$0.09 | -$0.09 |